Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponesimod in Chronic GVHD
NCT02461134Phase 2Terminated
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Sep 2016
- Primary completion
- Mar 2017
- Modality
- Covalent Small Molecules, Molecular Glues, Classical Binding Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of ponesimod in chronic graft-versus-host disease (cGVHD), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Change in Peripheral Absolute Lymphocyte Count From Baseline at 12 weeks. Started Sep 2016; status: terminated.
02
Drugs
ponesimod
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT02461134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02461134.